GSK Dutasteride sNDA Seeks Urinary Retention, Reduced Surgery Claims
Executive Summary
GlaxoSmithKline is seeking claims for reduced risk of acute urinary retention and reduced need for surgery related to benign prostatic hyperplasia in a supplemental NDA filing for dutasteride